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Abstract—The underglycosylated form of the MUC1 glyco-
protein, uMUC1, has been identiﬁed as a ligand for both E-
selectin and ICAM-1 and can play multiple potential roles
during rolling and ﬁrm adhesion events in the metastatic
cascade. Using ﬂow cytometry and confocal microscopy, the
T47D and ZR-75-1 cell lines were veriﬁed to highly express
uMUC1, however it was found that only ZR-75-1 cells
expressed the E-selectin binding moiety sialyl Lewis x (sLex).
Furthermore, perfusing T47D cells through E-selectin coated
microtubes resulted in fast rolling velocities and low numbers
of interacting cells and blocking uMUC1 with the SM3
antibody had no effect. ZR-75-1 cells, on the other hand,
were highly dependent on the E-selectin:uMUC1 interaction
as exempliﬁed by signiﬁcant increases in cell rolling velocities
and decreases in the number of interacting cells when
blocking with SM3 or when uMUC1 expression was knocked
down via siRNA transfection. Whereas uMUC1 interactions
with E-selectin supported cell rolling, P-selectin: uMUC1
interactions exclusively facilitated cell tethering, while L-
selectin surfaces supported no cell adhesive interactions.
These experimental observations are consistent with molec-
ular dynamics simulations of uMUC1 bound to E-, P-, and
L-selectin where the degree of residue contact correlated with
the differential adhesion of uMUC1 to each selectin. Finally,
an E-selectin and SM3 combined surface coating captured
approximately 30% of the total number of interacting cancer
cells comparable to the number of adhered cells when
utilizing E-selectin and ICAM-1 combined surfaces. The E-
selectin/SM3 surface strategy offers a viable method to
selectively capture cancer cells from whole blood samples.
Keywords—E-selectin, P-selectin, L-selectin, MUC1, ICAM-1,
Glycosylation, Sialyl Lewis x, Breast cancer, Circulating
tumor cells.
INTRODUCTION
Leukocyte recruitment to the inﬂamed endothelium
and cancer metastasis through the bloodstream via
circulating tumor cells (CTCs) have been proposed to
share a similar stepwise mechanism that allows for cell
adhesion and extravasation.12,28,31,33,36 Referred to as
adhesion cascades (leukocyte and CTC), cells ﬁrst te-
ther and roll on the blood vessel wall via transient
interactions between P- and E-selectin present on the
inﬂamed endothelium4,36 and carbohydrate moieties,
such sialyl Lewis x (sLex) or sialyl Lewis a (sLea) found
on leukocytes and CTCs.34,35 Sufﬁciently slow cell
rolling permits ﬁrm cell adhesion events mediated by
endothelial intercellular adhesion molecule-1 (ICAM-
1) at locations of transendothelial migration.2,11 Work
by our group has capitalized on these selectin:carbo-
hydrate based interactions to capture CTCs as well as
hematopoietic stem and progenitor cells with the
ability to maintain cell viability.18,19,29,30 Further dif-
ferentiation between CTCs and contaminating leuko-
cytes will allow isolation processes to be further
optimized with respect to both yield and purity.
Three cell adhesion molecules constitute the mem-
bers of the selectin family. E-selectin, primarily
expressed by inﬂamed endothelial cells, has been
extensively studied for its role in leukocyte recruitment
in response to vascular injury24 as well as CTC adhe-
sion.12,20 P-selectin is a granule protein expressed by
both platelets and endothelial cells, and therefore has
been linked to the adhesion of platelets,15 leukocytes,25
and cancer cells21 to the endothelium. L-selectin differs
in that it is expressed by leukocytes, not endothelial
cells, and therefore is not normally considered in the
context of cancer cell adhesion. All selectins contain
the epidermal growth factor and lectin domains where
the carbohydrate moieties can bind via calcium
dependent interactions.26 These carbohydrate moieties
are attached to O-glycosylated proteins on the cell
surface, referred to as selectin ligands, and in the
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context of cell adhesion to the vascular wall, both the
metastatic and leukocyte adhesion cascades rely on
similar selectin ligands to facilitate initial tethering and
rolling events.3,41
Leukocytes express three main selectin ligands: P-
selectin glycoprotein ligand 1 (PSGL-1), E-selectin li-
gand (ESL-1), and CD44.17 CTCs, on the other hand,
not only potentially express these three selectin
ligands7,39 but also a myriad of other selectin ligands
such as CD24, CD43, carcinoembryonic antigen
(CEA), and podocalyxin-like protein (PCLP).1,38,39,43
Recently two novel E-selectin ligands, mainly present
on breast cancer cells, have been postulated: Mac-
2BP32 and MUC1.10,42,43 Interestingly, the undergly-
cosylated form of MUC1 (uMUC1) has been shown to
be highly expressed in various breast cancer cells6,27
and clinically, high uMUC1 expression is correlated to
poor prognosis and increased metastases.40 Moreover,
the core of MUC1 has also been shown to be an
ICAM-1 ligand.16 Motivated by these ﬁndings, we re-
cently elucidated the synergistic role of uMUC1 as
both an E-selectin and ICAM-1 ligand during the CTC
adhesion cascade.14
Although selectin ligands can potentially bind to all
three selectins via calcium:carbohydrate dependent
binding, selectin ligands often preferentially bind to
particular selectins. Hidalgo et al.17 clariﬁed the spe-
ciﬁc functions of each selectin ligand during the leu-
kocyte adhesion cascade. PSGL-1, which preferentially
binds to P- and L-selectin,35 was found responsible for
the initial capture and tethering of leukocytes. ESL-1,
which preferentially binds to E-selectin,37 generated
rolling cells from tethering events. Lastly, CD44
interactions with E-selectin have been found to control
cell rolling velocity.17 L-selectin (present on leuko-
cytes) is polarized after leukocyte ﬁrm adhesion where
further possible interactions with PSGL-1 on other
leukocytes in the bloodstream can occur. It is also
possible for L-selectin to interact with E-selectin on the
endothelium to further enhance cell capture.44 Our
group has exploited this selectin preference while
studying the efﬁciency of halloysite nanotubes on CTC
capture,18,19 where P-selectin was utilized when cells
expressed PSGL-1 and E-selectin was used otherwise.
We have also found that pathologically decreasing
extracellular pH can enhance PSGL-1 binding to P-
and L-selectin, while having no effect on E-selec-
tin:PSGL-1 binding.5 Taken together, the use of dif-
ferent selectins can offer another axis of control to
more efﬁciently and selectively capture CTCs.
In our previous study of MUC1, we examined the
adhesion proﬁles of ZR-75-1 and MCF7 cells on
combined surfaces of E-selectin and ICAM-1.14 We
found that whereas both cell lines exhibited high levels
of MUC1, only ZR-75-1 cells exhibited uMUC1 which
leads to slower rolling velocities (facilitated by E-
selectin) and the existence of ﬁrm adhesion events
(facilitated by ICAM-1) which strongly suggested that
the uMUC1 glycoprotein signiﬁcantly participates in
the adhesion of metastatic cancer cells to the inﬂamed
endothelium. To extend the E-selectin/ICAM-1 com-
bined surface study in the context of cell adhesion
facilitated by uMUC1, we ﬁrst utilize the ZR-75-1 and
T47D cell lines, which both have been shown to ex-
press high levels of uMUC1, to further characterize the
differential adhesion of uMUC1 to E-selectin coated
surfaces. We then explore the preferential binding of
uMUC1 to E-, P-, and L-selectin via experimental
rolling assays under shear stress and molecular
dynamics (MD) simulations. Since uMUC1 is only
expressed by CTCs in the bloodstream, we further
hypothesize that utilizing a combined E-selectin and
SM3 (antibody that speciﬁcally binds to uMUC1)
surface may provide a novel approach to target CTCs
for capture or treatment, where the E-selec-
tin:uMUC1 interactions facilitate cell rolling and the




Recombinant human E-selectin-IgG chimera was
purchased from R&D systems (Minneapolis, MN).
Blotting grade blocker non-fat dry milk was purchased
from Bio-Rad Laboratories (Hercules, CA) and Pro-
tein-G was purchased from EMD Biosciences (San
Diego, CA). FITC mouse anti-human CD227 (clone
HPMV), FITC Mouse IgG1 k isotype control, puriﬁed
mouse anti-human CD15s (clone CSLEX), APC rat
anti-mouse IgM, FITC mouse anti-human CD44, and
FITC goat anti-mouse IgG/IgM were all purchased
from BD Biosciences (San Jose, CA). Mouse anti-hu-
man MUC1 mAb clone SM3 (recognizing the under-
glycosylated form of MUC1) was purchased from
Abcam (Cambridge, MA). Mouse anti-human CA19-9
(sLea) was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). APC anti-human IgG antibodies
were purchased from Invitrogen (Carmarillo, CA).
Ca2+ and Mg2+ free DPBS (Invitrogen, Camarillo,
CA, USA), calcium carbonate (Sigma Chemical Co.,
St. Louis, MO, USA), and low endotoxin (1 ng/mg),
essentially globulin-free Bovine Serum Albumin (Sig-
ma Chemical Co., St. Louis, MO, USA) were used to
prepare ﬂow buffer for cell adhesion assays. CELL-
viewTM glass bottom dishes from Greiner Bio-One
were used to plate cells for confocal microscopy
experiments.
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Breast Cancer Cell Culture
Breast cancer cell lines ZR-75-1 and T47D were
purchased from ATCC and maintained in 10% Fetal
Bovine Serum (FBS; Cellgro), 1% penicillin–strepto-
mycin (Invitrogen), and RPMI 1640 medium at 37 C
with 5% CO2 in a humidiﬁed incubator.
Flow Cytometry
Cells were removed from tissue culture ﬂasks prior
to antibody incubation using an enzyme-free cell dis-
sociation buﬀer solution. After washing with 19
DPBS, the cells were resuspended in 1% BSA in DPBS
to a ﬁnal concentration of approximately 250,000 cells
per sample. Antibodies against MUC1 or appropriate
isotype controls were added to the cell suspensions and
incubated over ice for 45 min. Speciﬁcally, mouse an-
ti-human MUC1 mAb clone HPMV (reacts with the
peptide core of MUC1) and mouse anti-human MUC1
mAb clone SM3 (recognizing the underglycosylated
form of MUC1) were used in this study. Antibodies
against CD44, sLea, and sLex were also used in this
study to quantify the ligand and glycan expression on
both cell types. Following incubation, cells were wa-
shed twice with 500 lL of 1% BSA to remove any
unbound antibody. Flow cytometry samples were
analyzed using a BD Accuri C6 ﬂow cytometer (Ann
Arbor, MI).
Confocal Immunoﬂuorescence Microscopy
ZR-75-1 and T47D cells were plated in CELL-
viewTM glass bottom dishes overnight prior to imag-
ing. Surface staining for MUC1 and uMUC1 was
performed using mouse anti-human CD227 mAb,
mouse anti-human MUC1 mAb (clone SM3), and
Alexa 647 rat anti-mouse mAb as a secondary anti-
body as described in Geng et al.14 Cells were also
incubated with conjugated human recombinant E-
selectin chimera for 30 min at room temperature (RT).
A Zeiss 710 laser scanning confocal microscope at
the Cornell University microscopy and imaging
core facility was used to collect images using a 409
objective.
Preparation of Immobilized Protein Surfaces
Polyurethane microtubes with an inner diameter of
300 lm (Braintree Scientiﬁc Inc., Braintree, MA, USA)
were cut to a length of 50 cm. Recombinant human E-
selectin-IgG chimeric protein was dissolved in 19 PBS to
a ﬁnal concentration of 5 lg/mL. The microtube surface
was ﬁrst rinsed with 75% ethanol and then 19 PBS. The
surface was subsequently incubated with 10 lg/mL pro-
tein-G solution for 1.5 h, followed by a 2 h incubation
with selectin chimera then blocked with 5%milk protein
in PBS for 1 h. Control tubes were blockedwith 5%milk
protein in PBS for 1 h.
Flow-Based Adhesion Assay
Microtubes functionalized with E-selectin/Fc chi-
mera (described above) were taped onto a piece of thin
glass in the viewing area of the Olympus IX81 inverted
microscope (Olympus America Inc., Melville, NY,
USA). A CCD camera (model no: KP-M1AN, Hit-
achi, Tokyo, Japan) and a DVD recorder (model no:
DVD-1000MD, Sony Electronics) were used to record
experiments for oﬄine analysis. ZR-75-1 and T47D
breast cancer cells suspended in ﬂow buﬀer containing
calcium were perfused through the microtubes using a
syringe pump (KDS 230, IITC Life Science, Woodland
Hills, CA) at a wall shear stress of 1.0 dyne/cm2.
Neuraminidase Treatment
For certain experiments, ZR-75-1 and T47D cells
were treated with 0.1 U/mL Vibrio Cholerae Neur-
aminidase (Roche Applied Science, Indianapolis, IN)
for 45 min at 37 C to cleave the terminal sialic acid
residues. After enzyme treatment cells were washed
and perfused through the functionalized microtubes.
siRNA Transfection
Cells were transfected with 20 nM of MUC1 siRNA
(QIAGEN) for 12 h. Total RNA was isolated from
transfected cells using TRIzol (Life Technologies).
Real-time PCR was carried out using oligo dT ﬁrst
strand primers, MUC1 speciﬁc primers [(5¢-TGCAT
CAGGCTCAGCTTCTA-3¢ and 5¢-GAAATGGCA
CATCACTCACG-3¢, IDT Integrated DNA Technol-
ogies], and SYBR Green PCR Kit (QIAGEN). MUC1
expression was normalized against GAPDH.
Polymorphonuclear Neutrophil (PMN) and Buﬀy Coat
Isolation
Human peripheral blood was collected from healthy
adult donors after informed consent by venipuncture
into BD Vacutainer tubes, as approved by the Cornell
University Institutional Review Board for Human
Participants. PMN isolation was performed following
a protocol described previously.13 Brieﬂy, PMNs were
isolated by centrifugation at 500 g for 50 min using
1-Step Polymorphs (Accurate Chemical and Scientiﬁc
Corporation, Westbury, NY, USA). The PMN layer
was extracted and washed twice in Ca2+ and Mg2+
free HBSS to remove the polymorph residue, and any
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remaining red blood cells were lysed hypotonically
with 1:6 and 49 PBS. PMNs were then resuspended at
various concentrations of HBSS containing 0.5%
HSA, 2 mM Ca2+, and 10 mM HEPES, buffered to
7.4. Similarly, buffy coat layer isolation was performed
using Ficoll density gradient and washed with HBSS.
Cancer Cell Capture from Spiked Buﬀy Coat
ZR-75-1 cells were ﬂuorescently labeled with Cell
Tracker Green (Invitrogen), a live cell dye, for 30 min
at 37 C. 100,000 or 50,000 of the labeled ZR-75-1 cells
were then spiked into 1 mL of normal buﬀy coat and
perfused through protein coated microtubes in two
separate experiments. Capture eﬃciency was calculated
using the estimated total number of cells in the
microtube from 20 images recorded at random loca-
tions along the length of the microtube based on a
previously published calibration.19
Data Acquisition and Analysis
‘‘Rolling’’ cells were deﬁned as those observed to
translate in the direction of ﬂow with an average
velocity less than 50% of the calculated hydrodynamic
free stream velocity. The rolling velocity was calculated
by measuring the distance a rolling cell traveled over a
30 s interval. Videos of rolling cells were taken at three
randomly selected locations along the microtube. For
capture experiments, adherent cells were counted after
perfusion with cell-free buﬀer for 5 min. The quantities
of cells rolling and adhering were determined by
recording images at 20 randomly selected locations
along the microtube. All errors are reported as stan-
dard error of the mean, and statistical analyses were
performed using Prism (GraphPad Software, San
Diego, CA).
Molecular Dynamics Simulations
Free dynamics simulations were performed using
the YASARA (http://yasara.org) package of MD
programs with the YAMBER3 self-parameterizing
force ﬁeld23 and no external force ﬁeld parameters. All
simulations held the temperature and pressure con-
stant at 300 K and 1 atm, respectively, while utilizing
periodic boundary conditions, the particle mesh Ewald
method for electrostatic interactions,9 equilibrium pH
(7.4), and the recommended 7.86 A˚ force cutoff for
long-range interactions. Complexes were solvated in a
water box and neutralized by adding Ca2+ and Cl
ions to a concentration of ~ 50 mM calcium where the
water boxes were deﬁned as cubes with lengths mea-
suring approximately 85 A˚ to allow for free protein
rotation. The water boxes were also allowed to adjust
slightly to constrain the water density to 0.997 g/L.
Conformational stresses were removed via short
steepest descent minimizations followed by simulated
annealing until sufﬁcient convergences were reached.
Free dynamics simulations were then run for 20 ns
time periods.
The lectin and epidermal growth factor crystal
structures of P-selectin bound to PSGL-1 (1G1S35), E-
selectin bound to sLex (1G1T35), and L-selectin
(3CFW) were obtained from the Protein Data Bank
for use as starting atomic coordinates. Predicted
uMUC1 bound to P-selectin was obtained by altering
the PSGL-1 amino acid sequence of the P-selec-
tin:PSGL-1 complex (1G1S subunit A) to the uMUC 1
sequence where two amino acids were included beyond
the O-glycosylated site for consistency with the
PSGL-1 crystal structure. Extra amino acids were ex-
tended to include the entire 20 U uMUC1 sequence
(PDTRPAPGSTAPPAHGVTSA). In separate trials,
residues S9, T10, and T18 were O-glycosylated with the
carbohydrate moiety where sLex was coordinately
bound to the calcium of P-selectin. To obtain starting
E-selectin:uMUC1 and L-selectin:uMUC1 complexes,
the E-selectin (1G1T) and L-selectin (3CFW) crystal
structures were aligned on the various P-selec-




The surface expression of common selectin ligands
and their carbohydrate binding moieties was ﬁrst
characterized. Both T47D and ZR-75-1 cells were
found to express some amount of CD44 (Figs. 1a and
1e) while neither expressed PSGL-1 (data not shown,
also suggested by Shirure et al.32). These two cell lines
differed in their expression of the important selectin-
binding moieties sLea and sLex. T47D cells exhibited
very little sLea (Fig. 1b) and no sLex (Fig. 1c) while
ZR-75-1 cells showed signiﬁcant expression of both
sLea and sLex (Figs. 1f and 1g). The differential
expression of these selectin binding moieties resulted in
a greater preference of ZR-75-1 over T47D cells in
soluble E-selectin binding assays, as revealed by con-
focal microscopy (Figs. 1d and 1h). T47D cells, how-
ever, showed weak staining of bound E-selectin which
may be due to the minimal surface expression of sLea.
In previous research to examine the adhesive capa-
bilities of uMUC1, we utilized the ZR-75-1 and MCF7
cells lines due to their high expression of the MUC1
glycoprotein.14 It was found that while both cell lines
expressed MUC1, ZR-75-1 cells expressed signiﬁcantly
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more MUC1 as indicated by SM3 antibody staining.
The SM3antibody has been shown to bind to theMUC1
core epitope corresponding to the underglycosylated
form of MUC1 (uMUC1).8 We hypothesized that the
metastatic potential of ZR-75-1 cells (highly metastatic)
and MCF7 cells (weakly metastatic) correlate with the
FIGURE 1. Flow cytometry histogram plots of T47D (in red) and ZR-75-1 (in blue) cells labeled with anti-CD44 mAb (a, e), anti-sLea
mAb (b, f), and anti-sLex (clone CSLEX, c, g), respectively. Isotype controls are represented by solid gray peaks in each plot. (d, h)
Confocal microscopy images of T47D and ZR-75-1 cells labeled with pre-conjugated recombinant human E-selectin/Fc (shown in
green) and DAPI nucleic acid stain (shown in blue), respectively. Scale bar: 50 lm.
FIGURE 2. Flow cytometry histogram plots of T47D (in red) and ZR-75-1 (in blue) cells labeled with anti-MUC1 (CD227) mAb (clone
HPMV, a, e) and anti-uMUC1 mAb (clone SM3, c and g). (b, f) Confocal microscopy images of T47D and ZR-75-1 cells labeled with
anti-CD227 mAb (green) and DAPI nucleic acid stain (blue), respectively. (d, h) Confocal microscopy images of T47D and ZR-75-1
cells labeled with anti-uMUC1 mAb, respectively. Scale bar: 50 lm.
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expression of uMUC1. In this study, we tested the
MUC1 expression of T47D cells (weakly metastatic)
compared to ZR-75-1 cells. Interestingly, both cell lines
highly expressMUC1as revealed by theCD227 antibody
(Figs. 2a and 2e) and exhibited high expression of
uMUC1 as revealed by SM3 labeling and ﬂow cytometry
(Figs. 2c and 2g). Furthermore, both cell lines showed
strong homogeneous surface staining ofMUC1 (Figs. 2b
and 2f) and uMUC1 (Figs. 2d and 2h) via confocal
microscopy where ZR-75-1 cells showed greater staining
for both antibodies, indicating relatively higher MUC1
and uMUC1 expression over T47D cells. While MCF7
andZR-75-1 cells differentially expresseduMUC1,T47D
and ZR-75-1 cells varied only in their expression of the
carbohydrate binding moieties sLex and sLea.
Cell Rolling Assay
Lack of sLex expression generally suggests a lack of
selectin adhesive interactions under ﬂow conditions.
However, T47D cells interacted with the E-selectin
surface (consistent with confocal staining by soluble
E-selectin and likely due to sLea) which facilitated
rolling events, albeit extremely fast cell rolling veloci-
ties, >15 lm/s, and lower numbers of interacting
cells,< 15 cells/frame, for an E-selectin concentration
of 5 lg/mL (Figs. 3a and 3b). Increasing the E-selectin
concentration to 10 lg/mL signiﬁcantly decreased the
cell rolling velocities to ~5 lm/s and slightly increased
the number of interacting cells to ~18 cells/frame
indicating that cell interactions were indeed E-selectin
dependent. Furthermore, perfusing cells with uMUC1
blocked with SM3 through microtubes with 5 lg/mL
E-selectin concentration resulted in no signiﬁcant
change in cell rolling velocities or number of interact-
ing cells, suggesting that the E-selectin binding moiety
responsible for these weak interactions was most likely
not presented by MUC1.
Thus, the hypothesized correspondence between
uMUC1 expression and metastatic potential must be
FIGURE 3. Adhesion phenotype of T47D (in red) and ZR-75-1
(in blue) cells represented by their rolling velocity on E-
selectin coated surface (a) and average number of cells
observed on the surface (b). E-sel, P-sel, and L-sel indicate
the surface proteins E-selectin, P-selectin, and L-selectin,
respectively. Numbers following the surface protein abbrevi-
ations denote the surface protein concentration in lg/mL, for
example ‘‘E-sel5’’ signifies that the surface protein E-selectin
at a concentration of 5 lg/mL was utilized. Combined surfaces
of E- and P-selectin were utilized with constant E-selectin
concentrations (5 lg/mL) and varying P-selectin concentra-
tions (10 and 25 lg/mL) and are denoted as ‘‘E-sel5 P-sel10’’
and ‘‘E-sel5 P-sel25,’’ respectively. Text in parentheses fol-
lowing the surface protein indicators denote specific treat-
ments of either ZR-75-1 or T47D cells where (SM3 Blocked)
and (Neuraminidase) indicates that cells were incubated with
either anti-SM3 neutralizing antibody or neuraminidase,
respectively. (siRNA) indicates that cells were transfected
with MUC1 siRNA. Absence of parentheses indicates that no
such treatments were performed. Student’s t test was per-
formed for all results compared to E-sel5 within each cell line.
Combined surfaces E-sel5 P-sel10 and E-sel5 P-sel25 for the
ZR-75-1 cell line were also paired. All significances are
p< 0.001, unless otherwise indicated by **p< 0.01, *p< 0.05, or
NS (not significant). (c) Quantification of MUC1 mRNA level
knockdown efficiency via qPCR. (d) Quantification of cell
surface MUC1 protein level knockdown efficiency via flow
cytometry (mean fluorescence intensity index was plotted).
b
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amended to include the expression of sLex, since T47D
cells (weakly metastatic) express uMUC1 but not sLex.
ZR-75-1 cells, on the other hand, showed greater
interactions with the E-selectin coated microtubes
yielding slower cell rolling velocities of ~3 lm/s and
greater numbers of interacting cells, nearly 39 cells/
frame, for the 5 lg/mL concentration of E-selectin
(Figs. 3a and 3b), consistent with the evident expres-
sion of sLex on the cell surface. Doubling the E-selectin
concentration signiﬁcantly decreased the cell rolling
velocities to ~2 lm/s while only slightly increasing the
number of interacting cells to around 40 cells/frame.
SM3 blocking of ZR-75-1 cells nearly doubled the cell
rolling velocity and dramatically decreased the number
of interacting cells to about 6 cells/frame. This dem-
onstrates the interruption of the E-selectin:uMUC1
interaction as ﬁrst described in previous work.14
Inhibiting sLex moieties from the cell surface via
neuraminidase treatment signiﬁcantly increased cell
rolling velocities to >7 lm/s and decreased the num-
ber of interacting cells to ~ 13 cells/frame, further
demonstrating the importance of the sLex binding
moiety. Finally, knocking down MUC1 via siRNA
transfection yielded an effect similar to SM3 blocking
where cell rolling velocities signiﬁcantly increased to
4.3 lm/s and the number of interacting cells decreased
to ~ 13 cells/frame. After siRNA treatment, as indi-
cated in Figs. 3c and 3d, both mRNA and protein
levels of MUC1 were reduced by at least 50% com-
pared to the control ZR-75-1 cells.
Interestingly, perfusing ZR-75-1 cells through P-
selectin coated microtubes produced around 25 inter-
acting cells/frame (Fig. 3a), however, no cells were
found rolling or ﬁrmly adhered to the surface
(Fig. 3b). This interaction was abolished after siRNA
knockdown of uMUC1. Therefore, the P-selec-
tin:uMUC1 interaction facilitated tethering events
where cells experienced momentary arrest to the sur-
face followed by rapid release of the cells into the ﬂow
buffer. Furthermore, perfusing ZR-75-1 cells through
combined E- and P-selectin coated microtubes resulted
in around 50 interacting cells/frame, signiﬁcantly more
than E-selectin only surfaces (Fig. 3a), where cell
rolling velocities increased nearly double compared to
E-selectin-only surfaces (Fig. 3b). This further indi-
cates the speciﬁc role of P-selectin for cell tethering
rather than cell rolling. Perfusing cells through L-
selectin coated microtubes did not produce any inter-
acting cells indicating that the L-selectin:uMUC1
interaction is too weak to inﬂuence cell motion.
FIGURE 4. Equilibrated uMUC1 (magenta) and sLex (orange) structures bound to E-selectin (green). With respect to the uMUC1
sequence, PDTRPAPGSTAPPAHGVTSA, the top and bottom rows correspond with the ‘‘reverse’’ and ‘‘forward’’ sequence,
respectively. uMUC1 residues S9 (a, b), T10 (c, d), and T18 (e, f) are glycosylated as indicated by the uMUC1 sequence and the




Tofurther explore thediﬀerential interactionsbetween
the uMUC1 glycoprotein and each selectin, MD simu-
lations were used to dock several O-glycosylated variants
of uMUC1 to E-, P-, and L-selectin. Figure 4 shows E-
selectin:uMUC1 complexes where the S9 (Figs. 4a and
4b), T10 (Figs. 4c and 4d), and T18 (Figs. 4e and 4f)
amino acid sites of the uMUC1 core epitope were O-
glycosylated with a sLex moiety. Sites T3 and S19 sites
were not tested because these sites should not be in a
glycosylated form as suggested by SM3 binding.8 Each
variant of uMUC1binding indicated a different degree of
residue contact. In the majority of cases, residues R108
and K112 experienced hydrogen bonding interactions,
where both residues interacted with the core epitope of
uMUC1 exclusively and not sLex. On the other hand,
residue R97 only interacted with the sLex forming
hydrogen bonds in Figs. 4a, 4d, and 4e. In a single case
(Fig. 4e, site T18) all three residues formed contacts and
since the PSGL-1 glycoprotein is considered a P-selectin
speciﬁc ligand due to enhanced interactions facilitated
by the R85 and H114 residues of P-selectin,35 these MD
results suggest that the uMUC1 glycoprotein can be
regarded as an E-selectin speciﬁc ligand.
Figure 5 depicts the uMUC1 interactions with P-
selectin (top) and L-selectin (bottom), where one of
each S9 (Figs. 5a and 5b), T10 (Figs. 5c and 5d), and
T18 (Figs. 5e and 5f) glycosylated site is shown for
clarity. In the case of P-selectin, residues R85, H108,
and K112 formed hydrogen bonding contacts to the
uMUC1 core epitope. For L-selectin, only residues
R97 and K111 formed contacts where both residues
contacted sLex and not the uMUC1 core epitope.
Again, glycosylating the T18 site of uMUC1 yielded
the most interactions for both P-selectin and L-selectin
(Figs. 5e and 5f, respectively). In comparison with E-
selectin, P-selectin lacked residue R97 to form contacts
with sLex whereas L-selectin lacked residues R108 and
K112 to form contacts with the uMUC1 core epitope.
Thus, to qualitatively interpret the experimental rolling
assays, E-selectin facilitates cell rolling due to its ability
to contact both the uMUC1 core epitope and sLex. P-
selectin effectively tethers cells due to its ability to
contact the uMUC1 core epitope but was unable to
produce cell rolling possibly because of insufﬁcient
binding with sLex. Lastly, L-selectin initiated no
interacting cells due to its inability to interact speciﬁ-
cally with uMUC1. These data suggest that uMUC1
FIGURE 5. Equilibrated uMUC1 (magenta) and sLex (orange) structures bound to P-selectin (gray, top row) and L-selectin (blue,
bottom row). With respect to the uMUC1 sequence, PDTRPAPGSTAPPAHGVTSA, all interactions correspond with the ‘‘reverse’’
sequence. uMUC1 residues S9 (a, b), T10 (c, d), and T18 (e, f) are glycosylated as indicated by the uMUC1 sequence and the orange
arrow. The atoms of select P-selectin amino acids (R85, H108, and K112) and L-selectin amino acids (R97 and K111) are depicted to
show varying degrees of contacting residues.
Underglycosylated MUC1 as a Breast Cancer Target 155
can be considered as both an E- and P-selectin speciﬁc
ligand where each selectin facilitates different roles in
the metastatic adhesion cascade, whereas L-selectin
most likely plays no part in functional uMUC1
binding.
Capturing Breast Cancer Cells Using uMUC1 mAb
Applying these insights into the selective adhesion
of the uMUC1 glycoprotein, a combined E-selectin
and SM3 surface was prepared to capture cancer cells.
It was found that SM3 bound minimally to PMNs
(Fig. 6a) via ﬂow cytometry, with the mean ﬂuores-
cence intensity index signiﬁcantly lower compared to
ZR-75-1 cells (Fig. 6b). Perfusing ZR-75-1 cells
through a microtube coated with only E-selectin
resulted in nearly 50 rolling cells/frame (Fig. 6c) with
no adherent cells on the surface. Coating the microtube
surface with both E-selectin and SM3 did not change
the number of rolling cells, but allowed for ﬁrm
adhesion events facilitated by SM3:uMUC1 interac-
tions where subsequent perfusion of buffer resulted in
an average of over 17 captured cells/frame. The ratio
of ﬁrm adhesion events to total number of cells found
on the protein coated surface was comparable to the
ratio for the E-selectin/ICAM-1 combined surface as
studied previously.14 Perfusing isolated PMNs over the
same E-selectin/SM3 combined surface resulted in over
50 rolling events per frame with no adherent cells.
Furthermore, since ICAM-1 also facilitates ﬁrm
adhesion events with leukocytes, the E-selectin/SM3
combined surface may provide a more selective meth-
od to separate CTCs from whole blood.
Processing normal buﬀy coat spiked with Cell
Tracker labeled ZR-75-1 cells through microtubes
coated with E-selectin only or E-selectin with SM3
antibody resulted in capture eﬃciencies of 0.4 and
26.7%, respectively (Fig. 6d). Here, ‘‘captured’’ cells
refers to the number of ﬁrmly adherent cells. Cells that
were effectively captured by this combined surface
strategy must express both the sLex glycan and the
uMUC1 glycoprotein. The sLex glycan facilitates the
initial tethering and rolling events due to its interac-
tions with surface E-selectin when presented by
uMUC1 or other E-selectin ligands such as CD44.
Cells that initiate stable cell rolling can then form ﬁrm
adhesion events due to the interaction of uMUC1 and
the surface SM3. Therefore, uMUC1 and sLex
expression is essential for cell capture, whether or not
the sLex is found on uMUC1. However, our current
and previous results indicated that sLex terminated
uMUC1 is an E-selectin speciﬁc ligand that effectively
contributes to cell rolling. Moreover, of the three cell
lines studied here and previously, only the highly
metastatic ZR-75-1 cells expressed both sLex and
uMUC1 where uMUC1 was found to be decorated
with sLex. The capture percentage of non-cancer cells
was not presented in this study due to high variance of
blood cell count between donor buffy coats. Further-
more, due to the high degree of ZR-75-1 cell aggre-
gation, the spiking cell concentration performed in this
FIGURE 6. (a) Flow cytometry histogram plot of isolated
PMNs labeled with anti-uMUC1 mAb (clone SM3, in blue) and
isotype control (in gray). (b) Mean fluorescence intensity
quantification of uMUC1 expression of ZR-75-1 cells (in black)
and PMNs (in gray). (c) Average total number of ZR-75-1 cells
(left and middle bar sets) and PMNs (right bar set) observed
on surfaces coated with E-selectin at a concentration of
5 lg/mL (E-sel5) and the combination of E-selectin and SM3 at
concentrations of 5 and 50 lg/mL, respectively (E-sel5 SM3
50). Columns in gray indicate the average number of cells
(either ZR-75-1 or PMNs) while perfusing with cell solution
and columns in white indicate the average number cells
quantified after washing the surfaces with flow buffer for
5 min. Student’s t test was performed for both comparisons.
***p< 0.001; **p< 0.01; *p< 0.05. NS: not significant. (d) Num-
bers of captured ZR-75-1 cells from cancer cell spiked buffy
coat on surfaces coated with E-selectin (5.0 lg/mL) and the
combination of E-selectin (5.0 lg/mL) and SM3 (50 lg/mL).
Two separate experiments were performed with 100,000 cells
(24,176 captured) and 50,000 cells (14,587 captured), resulting
in 24.2 and 29.1% yield, respectively.
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study was much higher than clinical values as well as
concentrations used in our previous studies using
clinically-motivated devices.18,19 Although at the
proof-of-concept stage, the combined E-selectin/SM3
surface described in this study shows potential for
selectively capturing CTCs expressing uMUC1.
CONCLUSIONS
In previous work, we examined two cell lines
(MCF7 and ZR-75-1) that exhibited variants of the
MUC1 glycoprotein where both cell lines expressed
MUC1, however only ZR-75-1 expressed the under-
glycosylated form uMUC1. We had previously found
that uMUC1 has the ability to interact with E-selectin
and ICAM-1 and, for these two cell lines, the meta-
static potential corresponded with uMUC1 expression
since ZR-75-1 cells are highly metastatic and MCF7
cells are weakly metastatic.14 Here, we further explored
the function of uMUC1 during the metastatic adhesion
cascade by extending the study to the T47D cell line
(weakly metastatic). It was found by examining vari-
ous E-selectin ligands that T47D and ZR-75-1 cells
differed only in their expression of the E-selectin
binding moiety sLex where T47D cells lacked this
expression. Without sufﬁcient sLex, T47D cells showed
little interaction with E-selectin coated microtubes,
resulting in extremely fast rolling velocities and low
numbers of interacting cells. Thus, for these three cell
lines, the metastatic potential seems to correlate with
the expression of uMUC1 as well as sLex.
ZR-75-1 cell interactions with E-selectin, however,
were highly dependent on uMUC1 expressionwhere cell
velocities signiﬁcantly decreased when uMUC1 was
blocked with either the SM3 antibody or uMUC1 siR-
NA knockdown. Moreover, uMUC1 interactions with
P-selectin exclusively facilitated cell tethering events on
P-selectin-only and E- and P-selectin combined surfaces
whereas L-selectin surfaces produced no cell interac-
tions. Utilizing MD simulations, E-selectin was shown
to interact with uMUC1 via three distinct residue con-
tacts to both the uMUC1 core epitope and sLex. On the
other hand, P-selectin possessed three distinct contacts
that interacted with only the uMUC1 core epitope and
L-selectin only interacted with sLex. These MD data
suggest that speciﬁc interactions with both the core
epitope and sLex is required to produce cell rolling
events whereas interactions with just the core epitope
produce tethering events and interactions with only the
carbohydrate unit do not produce any cell interactions.
Based on these observations, we propose a combined
surface of E-selectin and SM3 to preferentially capture
cells exhibiting uMUC1. It was found that the E-selectin/
SM3 microtubes captured approximately 27% of the
number of interacting cancer cells. Since PMNs are not
targeted by the SM3 mAb, it is expected that this E-
selectin/SM3 surface strategymay oﬀer a novel and viable
method to selectively isolate cancer cells fromwholeblood.
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